Cancer Biology: Angiogenesis, VEGF, and Anti-Angiogenic Therapies

Added:

Vessel Co-option and Compensatory Resistance to Anti-Angiogenic Therapy

While anti-angiogenic therapies like bevacizumab (Avastin) were designed to starve tumors by blocking VEGF-mediated blood vessel growth, clinical outcomes have revealed significant limitations. A major counterpoint to the 'starve-a-tumor' model is that cancers quickly adapt to VEGF inhibition. Tumors can bypass these drugs through 'vessel co-option,' where cancer cells hijack existing healthy blood vessels instead of growing new ones, or 'vasculogenic mimicry,' where tumor cells themselves form fluid-conduction channels. Furthermore, the extreme oxygen deprivation (hypoxia) induced by anti-angiogenic drugs can backfire. Hypoxia activates hypoxia-inducible factors (HIFs), which trigger the release of alternative growth factors (such as FGF and angiopoietins) and promote epithelial-mesenchymal transition (EMT). This transition often makes the tumor more aggressive, invasive, and prone to metastasis. Consequently, anti-angiogenic therapies often extend progression-free survival only temporarily, without significantly improving overall survival, challenging the paradigm of VEGF inhibition as a standalone magic bullet.

Basic cellular biology of cancer, including uncontrolled cell division, tumor progression, and the concept of metastasis.
The anatomy and physiology of the circulatory system, specifically how blood vessels (endothelial cells and capillaries) deliver oxygen and nutrients to tissues.
Fundamental concepts of cell signaling, including how extracellular ligands bind to cell-surface receptors to trigger intracellular cascades.
The cellular response to hypoxia, particularly how low oxygen levels trigger transcription factors like Hypoxia-Inducible Factor (HIF).
Mechanisms of drug resistance to anti-angiogenic therapies, such as compensatory upregulation of alternative angiogenic factors like FGF and PDGF.
The clinical concept of 'vessel normalization' and how anti-angiogenic drugs are strategically combined with chemotherapy and immunotherapy.
The systemic side effects of VEGF inhibitors, including hypertension, arterial thromboembolism, and impaired wound healing.
Next-generation angiogenesis inhibitors, including endogenous inhibitors like angiostatin and endostatin, as well as novel gene-therapy delivery methods.
424.2K views3.8Klikes3:59@MechanismsInMedicineOriginal Release: 2012-10-29

Tumors require new blood vessel formation (angiogenesis) to sustain growth beyond a certain size; tumor cells secrete vascular endothelial growth factor (VEGF) and related proteins that stimulate endothelial cell proliferation, basement membrane degradation via matrix metalloproteinases, vessel permeability, and survival of new blood vessels, making VEGF signaling a key therapeutic target in cancer treatment.